SCHEMBL238844

SCHEMBL238844

c1cn2c(n1)CCCC2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL29261101 0.98 PDPK1 (0.45)
SCHEMBL173406 0.98 PDPK1 (0.45)
SCHEMBL3310781 0.98 PDPK1 (0.45)
SCHEMBL12604725 0.98 PDPK1 (0.45)
Hydrochloric Acid SCHEMBL5598004 0.98 PDPK1 (0.45)
SCHEMBL23335459 0.98 PDPK1 (0.45)
SCHEMBL3313192 0.98 PDPK1 (0.45)
Bromide SCHEMBL29016983 0.96 PDPK1 (0.44)
Hydrochloric Acid SCHEMBL28449794 0.96 PDPK1 (0.44)
SCHEMBL712267 0.93

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 507 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4704830-A2 MRGPRX2 INHIBITORS AND METHODS OF USE THEREOF Septerna, Inc. (US) 2026-03-11 EP claimed
WO-2024226914-A2 MRGPRX2 ANTAGONISTS AND METHODS OF USE THEREOF SEPTERNA, INC. (US) 2024-10-31 WO claimed
US-20240239792-A1 MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF ASIA VISION LIMITED (CN) 2024-07-18 US claimed
CN-116096717-A Imidazo [1,2-a ] pyridine and [1,2,4] triazolo [1,5-a ] pyridine derivatives as TLR9 inhibitors for the treatment of fibrosis 百时美施贵宝公司 2023-05-09 CN claimed
EP-3672952-B1 BENZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2022-12-14 EP claimed
WO-2019043372-A1 SUBSTITUTES SULFONYL AZACYCLES AS MODULATORS OF HEDGEHOG (HH) SIGNALLING PATHWAY E-THERAPEUTICS PLC (GB) 2019-03-07 WO claimed
EP-2029559-B1 ARYL-4-ETHYNYL-ISOXAZOLE DERIVATIVES HOFFMANN LA ROCHE (CH) 2009-08-05 EP claimed
US-7544704-B2 Aryl-4-ethynyl-isoxazole derivatives HOFFMANN-LA ROCHE INC. (US) 2009-06-09 US claimed
EP-2029559-A1 ARYL-4-ETHYNYL-ISOXAZOLE DERIVATIVES F. Hoffmann-Roche AG (CH) 2009-03-04 EP claimed
US-20070287739-A1 Aryl-4-ethynyl-isoxazole derivatives F. HOFFMANN-LA ROCHE AG (CH) 2007-12-13 US claimed
WO-2007137954-A1 ARYL-4-ETHYNYL-ISOXAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-12-06 WO claimed
US-20040254158-A1 Anticoagulants; atherosclerosis; strokes; thrombosis; cardiovascular disorders BRISTOL-MYERS SQUIBB COMPANY 2004-12-16 US claimed
EP-0533837-A4 INHIBITION OF 5-LIPOXYGENASE AND CYCLOOXYGENASE PATHWAY MEDIATED DISEASES SMITHKLINE BEECHAM CORP (US) 1994-11-17 EP claimed
US-5300497-A Broad spectrum antibiotics and bactericides; stable to beta-lactamase; effective against antibiotic-resistant bacteria TOYAMA CHEMICAL CO., LTD. (JP) 1994-04-05 US claimed
EP-0543263-A2 Benziimidazoles, pharmaceuticals containing them and process for their preparation Dr. Karl Thomae GmbH (DE) 1993-05-26 EP claimed
EP-0533837-A1 INHIBITION OF 5-LIPOXYGENASE AND CYCLOOXYGENASE PATHWAY MEDIATED DISEASES SMITHKLINE BEECHAM CORPORATION (US) 1993-03-31 EP claimed
US-5185330-A Penicillins/ad/ TOYAMA CHEMICAL CO., LTD. (JP) 1993-02-09 US claimed
WO-1991019497-A1 INHIBITION OF 5-LIPOXYGENASE AND CYCLOOXYGENASE PATHWAY MEDIATED DISEASES SMITHKLINE BEECHAM CORPORATION (US) 1991-12-26 WO claimed
JP-7252254-A None JP disclosed
US-4325954-A ANTIDEPRESSANTS LABORATOIRES JACQUES LOGEAIS (FR) 1982-04-20 US disclosed